Year: 2025
Type: article
Abstract: Researchers from the University of Heidelberg, who have been pioneers in the field of fibroblast activation protein inhibitor (FAPI) tracer development, have provided a perspective on whether such theranostics are happening ([1][1]). Their discussion reflects a deep understanding of
Source: Journal of Nuclear Medicine
Author: Rodney J. Hicks
Institutions: The University of Melbourne, St Vincent's Hospital Melbourne
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W4407212877